India & Natco Pharma
4 shared events · Importance 3 · Last updated Mar 31, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Business
India: India is a key battleground for weight-loss drugs due to its large obesity population and is experiencing significant competition between Novo Nordisk and Eli Lilly and Company.
Natco Pharma: Natco Pharma is one of the Indian generic drugmakers that will likely offer lower-priced versions of semaglutide once the patent expires.
Nov 11, 2025 · 6 articles
Business
Natco Pharma: Natco Pharma is one of several Indian companies that launched generic versions of semaglutide, increasing competition for Novo Nordisk.
Mar 30, 2026 · 8 articles
Business
Natco Pharma: Natco Pharma is a key player in launching generic semaglutide in India at a significantly lower price, aiming to capture a substantial share of the weight-loss drug market.
Mar 20, 2026 · 8 articles
Business
Natco Pharma: Natco Pharma continues to be an investor in Pee Safe.
Mar 17, 2026 · 6 articles
NEWSDESK
Explore this relationship live
Track how India and Natco Pharma interact across events, view sentiment trends, and discover connected entities.
Open Dashboard